All the premium content at PrimeInvestor

Paid subscribers can read timely, actionable recommendations from our experts!
A PrimeInvestor subscription gets you not just invaluable recommendations, rankings, and review tools. It keeps you up-to-date with the latest from the financial marketplace and tells you what you should be doing right now!
What has changed with REIT/InvIT taxation
Research Reports

What has changed with REIT/InvIT taxation

For Indian investors looking for regular income with the possibility of capital appreciation, Real Estate Investment Trusts (REITs) and Infrastructure Investment Trusts (InvITs) are good vehicles. These entities own a bunch of real estate or infrastructure assets that throw up regular cash flows and distribute over 90% of their cash flows to their investors. As both their income and the value of the real estate or infrastructure portfolio they own can rise over time, REITs and InvITs offer the prospect of rising income with capital gains.

Read More ยป
Mankind Pharma IPO: Invest or avoid?
Stocks

Mankind Pharma IPO: Invest or avoid?

Mankind Pharma, which operates in the domestic pharmaceuticals space, opens its Rs 4300 core IPO today. The issue is priced at a band of Rs 1,026 – Rs 1,080 per share of face value Re.1/-.

Read More ยป
Prime Fund Recommendation: A multi-asset fund for long-term portfolios
Mutual funds & ETFs

Prime Fund Recommendation: A multi-asset fund for long-term portfolios

Multi-asset allocation funds as a category are not easy to use. With funds in the category having the freedom to swing drastically between asset classes, the aspects to consider range from how asset allocation calls are taken, how much the allocation changes, whether this translates into returns, and finally what the taxation is going to be.

Read More ยป
Prime Stock Recommendation - A pharma stock available at a bargain
Stocks

Prime Stock recommendation: A pharma stock available at a bargain

Picking a stock in the pharma space is not easy. The businesses are complex and can leave you feeling like you are preparing for a mini-MBBS. Whatโ€™s more โ€“ no two companies are alike. To compound matters, it is also a heavily regulated space (and rightly so) with complex supply chains very often, heavily reliant on China. Not only do most end products have names that sound like tongue twisters but can be governed by complex patent regulations.

Premium article available only to subscribers.

Read More ยป
Login to your account
OR

Become a PrimeInvestor!

Get stock & mutual fund recommendations

or
Have an account?
Login To Your Account
OR
Donโ€™t have an account ? Register for free